MedTrace Logo

DC Combined With ICIs in the Treatment of Advanced Lung Cancer Resistant to ICIs

NCT06329908 · Status: RECRUITING · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2024-03-26

No results posted yet for this study

Summary

This is a single-center, single-arm, prospective clinical trial to investigate the safety and efficacy of Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.

Conditions

Interventions

DRUG

LG002

Neo-DCVac combined with ICIs in the treatment of advanced lung cancer resistant to ICIs.

Sponsors & Collaborators

  • Zhen-Yu Ding

    lead OTHER

Principal Investigators

  • Qing Li, MD · West China Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-09-27
Primary Completion
2024-09-30
Completion
2026-10-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06329908 on ClinicalTrials.gov